Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 12/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 11/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1978055 | 1.00 | BACE1 (0.48) | BACE1BACE2LMNAMAPTHTT | |
| SCHEMBL6925436 | 0.88 | BACE1 (0.45) | BACE1BACE2 | |
| SCHEMBL1976962 | 0.87 | BACE1 (0.53) | BACE1BACE2 | |
| SCHEMBL12981298 | 0.87 | BACE2 (0.56) | BACE1BACE2 | |
| SCHEMBL1976963 | 0.87 | BACE1 (0.53) | BACE1BACE2 | |
| SCHEMBL1978523 | 0.83 | BACE1 (0.46) | BACE1BACE2 | |
| SCHEMBL1976846 | 0.83 | BACE1 (0.46) | BACE1BACE2 | |
| SCHEMBL16182079 | 0.80 | BACE1 (0.44) | BACE1BACE2 | |
| SCHEMBL1976843 | 0.79 | BACE1 (0.48) | BACE1BACE2 | |
| SCHEMBL1976845 | 0.79 | BACE1 (0.48) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509966-B1 | AMINO OXAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-22 | — | — | EP | disclosed |
| EP-2509966-A1 | AMINO OXAZINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-10-17 | — | — | EP | disclosed |
| US-7964594-B1 | Amino oxazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964594-B1 | Amino oxazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-06-21 | — | — | US | disclosed |
| WO-2011070029-A1 | AMINO OXAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-16 | — | — | WO | disclosed |
| US-20110144098-A1 | AMINO OXAZINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-16 | — | — | US | disclosed |
| US-20110144098-A1 | AMINO OXAZINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144098-A1 | AMINO OXAZINE DERIVATIVES | BACE2, BACE1, PSEN2 | BACE1 2/4885BACE2 1/4885LMNA 2758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.